Key highlights
- FDA approves NUMELVI, a second-generation JAK inhibitor for dogs.
- NUMELVI targets pruritus from allergic dermatitis in dogs 6 months and older.
- Available in veterinary clinics nationwide by spring 2026.
- NUMELVI is highly selective for JAK1, minimizing interference with other JAKs.
FDA Approval
The U.S. FDA has approved NUMELVI (atinvicitinib tablets), a second-generation Janus kinase (JAK) inhibitor, for controlling pruritus associated with allergic dermatitis in dogs aged six months and older.
Availability
NUMELVI is expected to be available in veterinary clinics and hospitals across the United States by spring 2026.
Mechanism of Action
NUMELVI is a once-daily treatment that significantly reduces itch from the first dose. It is highly selective for JAK1, minimizing interference with the immune functions of other JAKs, and inhibits JAK1-dependent cytokines involved in itch and inflammation.
Target Audience
The product is designed for dogs as young as six months, addressing a common condition that affects up to 20% of cases in general veterinary practice.
